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Abstract
Background: Pulmonary infections caused by Pneumocystis jirovecii in immunocompromised host can be associated
with cysts, pneumatoceles and air leaks that can progress to pneumomediastinum and pneumothoraxes. In such cases,
it can be challenging to maintain adequate gas exchange by conventional mechanical ventilation and at the same
time prevent further ventilator-induced lung injury. We report a young HIV positive male with poorly compliant lungs
and pneumomediastinum secondary to severe Pneumocystis infection, rescued with veno-venous extra corporeal
membrane oxygenation (V-V ECMO).
Case presentation: A 26 year old male with no significant past medical history was admitted with fever, cough
and shortness of breath. He initially required non-invasive ventilation for respiratory failure. However, his respiratory
function progressively deteriorated due to increasing pulmonary infiltrates and development of pneumomediastinum,
eventually requiring endotracheal intubation and invasive ventilation. Despite attempts at optimizing gas exchange by
ventilatory maneuvers, patients’ pulmonary parameters worsened necessitating rescue ECMO therapy. The introduction
of V-V ECMO facilitated the use of ultra-protective lung ventilation and prevented progression of pneumomediastinum,
maintaining optimal gas exchange. It allowed time for the antibiotics to show effect and pulmonary parenchyma to
heal. Further diagnostic workup revealed Pneumocystis jirovecii as the causative organism for pneumonia and serology
confirmed Human Immunodeficiency Virus infection. Patient was successfully treated with appropriate antimicrobials
and de-cannulated after six days of ECMO support.
Conclusion: ECMO was an effective salvage therapy in HIV positive patient with an otherwise fatal respiratory failure
due to Pneumocystis pneumonia and air leak syndrome.
Keywords: Extra corporeal membrane oxygenation, Pneumocystis jirovecii pneumonia, Human immunodeficiency
virus, Pneumomediastinum
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Background
Lung protective ventilation and prevention of ventilator-
induced lung injury (VILI) are a cornerstone in the
management of Acute Respiratory Distress Syndrome
(ARDS) [1]. But implementing these strategies in patients
with poor lung compliance can lead to inadequate gas
exchange. The use of veno-venous extra corporeal mem-
brane oxygenation (V-V ECMO) to facilitate lung rest and
maintain optimal gas exchange has been significantly
growing in the past few years [2, 3].
Prognosis of the underlying disease, timing, quality
of life of survivors and the possibility of being lung
transplant candidate remain important considerations
for patient selection. There are concerns about initiating
ECMO support in immunocompromised patients espe-
cially those with underlying HIV (Human Immunodefi-
ciency Virus) infection and AIDS (Acquired Immune
Deficiency Syndrome) due to poor outcomes [4]. We
report a case of life threatening respiratory failure due
to severe Pneumocystis jirovecii infection complicated
by pneumomediastinum in a HIV infected patient who
was rescued by V-V ECMO.
Case presentation
A 26 year old male with no significant past medical history
presented to the emergency department with complaints of
fever, dry cough, difficulty in breathing and chest pain of
15 days duration. Initial assessment showed an averagely
built male with body mass index (BMI) 18.8 kg/m2 (normal:
18.5-24.9 kg/m2), fever (38.9 °C), tachycardia (heart rate
120/min, regular), tachypnea (respiratory rate 35/min), hyp-
oxia (pulse oximetry: 85 % on room air, PaO2: 55 mm Hg)
and normal blood pressure (126/76 mm Hg). Systemic
examination was unremarkable other than reduced air
entry at both lung bases. Blood investigations revealed
an elevated white cell count of 14.2 x 109/L (normal:
4.5-10 x 109/L), predominantly neutrophilic; serum
electrolytes, renal function, liver function, coagulation
profile were within normal limits; lactate was 2.2 mmol/L
(normal: <2 mmol/L) and procalcitonin was 0.6 ng/mL
(normal: <0.5 ng/mL). Blood cultures, sputum for gram’s
stain and nasal swab for viral polymerase chain reaction
(PCR) were collected. Chest x-ray showed bilateral middle
and lower zone air space opacities (Fig. 1a). After oxygen
supplementation via nasal cannula, fluid resuscitation and
empirical antimicrobial therapy (ceftriaxone 2 gm i.v. once
daily, azithromycin 500 mg i.v. once daily and oseltamivir
75 mg orally twice daily) patient was stabilized (PaO2
80 mm Hg on oxygen 2 L/min through nasal cannula) and
admitted to medical ward.
Due to worsening of respiratory function (respiratory
rate 30/min and PaO2 60 mm Hg on supplemental
oxygen 5 L/min through face mask) on the 2nd day post
hospitalization, patient was transferred to medical inten-
sive care unit (MICU). Non-invasive ventilation (NIV) via
face mask was initiated to improve respiratory parameters
Fig. 1 Chest x-ray of patient. a On admission: Bilateral middle and lower zone air space opacities with air bronchograms; b After application of
non-invasive ventilation: Subcutaneous emphysema around neck and axillary region, hyper-lucency around mediastinal structures suggestive of
pneumomediastinum and bilateral pulmonary infiltrates. c Post endotracheal intubation and ECMO cannulation
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and ceftriaxone was escalated to piperacillin/tazobactam
4.5 gm i.v. every 6 h; azithromycin and oseltamivir were
continued. Blood and respiratory samples collected ini-
tially did not reveal causative organism for pneumonia.
Over the next 2 days patient’s condition remained steady
with single organ (respiratory) failure requiring intermit-
tent NIV (averaging 16 h/day) with oxygen supplement
(FiO2 0.5). As the patient was neurologically appropriate
and understood his clinical condition, good adherence to
NIV was maintained. On Day 4 of ICU admission, pa-
tient’s respiratory function further deteriorated (respira-
tory rate 40/min; PaO2 50 mm Hg on FiO2 0.6) and chest
x-ray showed subcutaneous emphysema with pneumome-
diastinum in addition to bilateral pulmonary infiltrates
(Fig. 1b). After detailed discussion with the patient and ad-
dressing his concerns, he was intubated and mechanical
ventilation was initiated. This was followed by diagnostic
bronchoscopy with broncho-alveolar lavage (BAL) fluid
collection and CT (computerized tomography) scan of
chest which revealed bilateral diffuse ground glass opacity
with extensive basal consolidation and pneumomediasti-
num (Fig. 2). Bedside trans-thoracic echocardiography
showed good left ventricular function and non-dilated right
ventricle. Since serial imaging did not show worsening of
pneumomediastinum, it was managed conservatively.
Despite optimal sedation, analgesia and neuro-muscular
paralysis it was not possible to achieve adequate gas ex-
change with lung protective ventilation and hence, ‘Severe
Respiratory Failure’ team at our institution was consulted.
On evaluation by the Severe Respiratory Failure team
(Table 1), tidal volume was decreasing to critical levels
(225 mL) trying to achieve safe ventilation pressures,
PaO2/FiO2 was 200 mm Hg on 45 % of FiO2 and 10 cm
H2O of Positive End-Expiratory Pressure (PEEP). As well
patient had severe respiratory acidosis with PaCO2 of
109 mm Hg and pH 7.01; pulmonary compliance was only
9 ml/cm H2O and Murray score was 3. The decision was
made to place the patient on V-V ECMO to facilitate lung
protective ventilation, prevent progression of pneumome-
diastinum and improve respiratory acidosis. 25 French
drainage cannula was inserted percutaneously into inferior
vena cava via left femoral approach and 23 French return
cannula was inserted into the inferior vena cava via right
femoral approach under fluoroscopy guidance. Post cannu-
lation, ECMO blood flow and sweep flow were titrated to 4
liters/min each in order to achieve optimal gas exchange.
Mechanical ventilation was switched to ultra-protective
strategy using Pressure Control Ventilation (PCV) with
Peak Inspiratory Pressure (PIP) 15 cm H2O, PEEP 5 cm
H2O, respiratory rate 10/min and FiO2 21 %. Patient was
anticoagulated with intravenous heparin infusion targeting
an APTT of 50-70 s. Cotrimoxazole 250 mg i.v. every 6 h
(20 mg/kg/day of Trimethoprim) and prednisone 40 mg
twice daily through feeding tube were started after Pneumo-
cystis jirovecii was identified in the broncho-alveolar lavage
(BAL) fluid on ECMO day 1. Subsequently, serology con-
firmed HIV-1 infection with CD4+ cell count of 84/mm3 of
blood (normal: 600-1500/mm3 of blood) and HIV viral load
of 907,302 copies/mL. Patient’s respiratory parameters pro-
gressively improved (Table 1), his blood pressure was main-
tained without vasopressor support and other organs
function including the kidneys remained normal through-
out ECMO therapy and ICU stay. Neuro-muscular paralysis
was held on ECMO day 2 followed by weaning off sed-
ation on ECMO day 3. The patient was able to tolerate
pressure support ventilation (PSV) by ECMO day 4 and
he was successfully de-cannulated after 6 days of V-V
ECMO support. Patient was extubated the next day,
followed by aggressive physiotherapy/mobilization and
transfer to medical ward in the next 48 h. There were
no complications related to ECMO therapy in this pa-
tient during ICU stay and on follow-up post discharge.
Patient was explained about his diagnosis and highly
active anti-retroviral therapy (HAART: Efavirenz, Emtrici-
tabine and Tenofovir) was initiated in the medical ward.
He was discharged in good general condition after 21 days
of hospitalization with follow-up appointment in Infec-
tious Disease clinic.
Fig. 2 CT scan of patient. a At the level of arch of aorta. b Lung
bases. Shows bilateral diffuse ground glass opacity with extensive
basal consolidation. Pneumomediastinum: air in the anterior and
superior mediastinum
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Discussion
The frequency of ICU admission for Pneumocystis
pneumonia in immunocompromised patients is decreas-
ing but mortality is high if it progresses to respiratory
failure requiring mechanical ventilation [5]. The most
common manifestation on chest radiographs is bilateral
interstitial or alveolar opacities. Parenchymal/sub-pleural
cysts and pneumatoceles are frequently seen on CT scan.
Spontaneous pneumothorax can occur in up to 36 % of
patients with Pneumocystis jirovecii pneumonia [5, 6].
However, spontaneous pneumomediastinum is an un-
common complication with no reported incidence rates.
The mechanism of spontaneous pneumomediastinum
can be explained by the existence of a decreasing pres-
sure gradient between the alveoli and the lung intersti-
tium that can result in alveolar rupture. This leads to
the accumulation of air in the interstitium that circulates
centripetally through the venous sheaths to the hilum
and mediastinum as the pressure in the mediastinum is
lower than that of the lung periphery [7]. Our patient
developed pneumomediastinum while on NIV. Baro-
trauma is very uncommon and pneumothorax following
NIV occurs in less than 5 % of cases [8]. Development
of pneumomediastinum in Pneumocystis jirovecii pneu-
monia patient receiving NIV has been reported previ-
ously [9]. This could be explained by the rupture of pre-
existing pneumatoceles or cysts under the effect of posi-
tive pressure ventilation.
Acute respiratory distress syndrome (ARDS) is a life
threatening respiratory condition. The Berlin definition
classifies ARDS as mild, moderate and severe according
to the value of PaO2/FiO2 ratio (Table 2) [10]. The main
supportive therapy for ARDS is positive pressure
mechanical ventilation which helps to ensure adequate
oxygenation. A landmark trial conducted in the late
1990s by the ARDS Network compared conventional
tidal volume of 12 ml/kg with low tidal volume of
6 ml/kg and permissive hypercapnia. A 9 % absolute
Table 1 Ventilator and ECMO parameters
Pre-Intubation Post-Intubation ECMO Day 1 ECMO Day 2 ECMO Day 3 ECMO Day 4 ECMO Day 5 ECMO Day 6
Mode of Ventilation PSV (NIV) PCV PCV PCV PCV PSV PSV PSV
RR 40 35 10 10 10 25 25 22
PIP 16 35 15 15 15 13 11 11
PEEP 4 10 5 5 5 3 3 3
VT - 225 90 200 400 400 360 370
FiO2 40 % 45 % 21 % 21 % 21 % 30 % 30 % 30 %
P/F ratio - 200 - - - - - -
Blood Flow - - 4 3.78 3.75 3.7 3.6 3.6
Sweep Flow - - 4 2.5 1.0 0.5 0 0
pH 7.46 7.01 7.44 7.39 7.42 7.47 7.5 7.5
PaO2 73 90 83 161 114 70 74 86
PaCO2 44 109 49 43 45 38 33 35
RR Respiratory rate, PIP Peak Inspiratory Pressure (cm H2O), PEEP Positive End Expiratory Pressure (cm H2O), VT Tidal volume (mL), FiO2 Fraction of inspired oxygen
(%), P/F ratio Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (mm Hg), PaO2 Partial pressure of oxygen in arterial blood (mm Hg), PaCO2
Partial pressure of carbon dioxide in arterial blood (mm Hg), NIV Non Invasive Ventilation, PSV Pressure Support Ventilation, PCV Pressure Control Ventilation
Table 2 ARDS Berlin definition
Timing: Within 1 week of a known clinical insult or new or worsening respiratory symptoms.
Chest imaginga: Bilateral opacities — not fully explained by effusions, lobar/lung collapse, or nodules.
Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload.
Need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenationb:
• Mild - 200 mm Hg < PaO2/FiO2 ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H2O
c
• Moderate - 100 mm Hg < PaO2/FiO2 ≤ 200 mm Hg with PEEP ≥5 cm H2O
• Severe - PaO2/FiO2≤ 100 mm Hg with PEEP ≥5 cm H2O
CPAP continuous positive airway pressure, FiO2 fraction of inspired oxygen, PaO2 partial pressure of arterial oxygen, PEEP positive end-expiratory pressure
aChest radiograph or computed tomography scan
bIf altitude is higher than 1000 m, the correction factor should be calculated as follows: [PaO2/FIO2*(barometric pressure/760)]
cThis may be delivered noninvasively in the mild acute respiratory distress syndrome group
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mortality reduction was found in the low tidal volume
ventilation group. In this study, target tidal volume
was calculated based on ideal body weight (IBW) with
targeted plateau pressures of <30 cm H2O and permis-
sive hypercapnia [1]. Our patient did not retain CO2
while breathing spontaneously or supported by NIV.
But soon after endotracheal intubation and mechan-
ical ventilation he developed severe hypercapnia. This
could be explained by the fact that during spontaneous
breathing patient was inhaling large tidal volumes which
resulted in increased minute ventilation and adequate
CO2 clearance at the expense of high trans-pulmonary
pressures resulting in worsening of air leak. After intub-
ation, sedation and paralysis; lung protective ventilation
was provided which resulted in severe (permissive) hyper-
capnia. Thus, ventilating this patient with ARDS and air
leak syndrome was challenging because a balance was to
be maintained between providing adequate gas exchange
and preventing worsening of pneumomediastinum. The
Extracorporeal Life Support Organization (ELSO) guide-
lines for Adult Respiratory Failure 2013 have listed carbon
dioxide retention on mechanical ventilation despite high
plateau pressures (>30 cm H2O) and severe air leak
syndrome as indications for initiating extracorporeal
life support [11]. Based on these recommendations we
provided ECMO therapy to our patient, as a bridge to
recovery from severe pulmonary infection.
There are very few case reports of ECMO therapy for
severe respiratory failure due to Pneumocystis pneumonia
in HIV/AIDS patients (Table 3) [9, 12–15]. All reported
patients required V-V ECMO support for primarily respira-
tory failure other than the case reported by Gutermann
et al, who was provided V-A (veno-arterial) ECMO therapy
post cardiac arrest. 5 out of 8 patients had concomitant
pneumothorax/pneumomediastinum which could have
possibly worsened the respiratory failure, necessitating
rescue ECMO therapy. The timing for initiation of V-V
ECMO in severe respiratory failure remains debatable.
However, based on previous studies it has been ob-
served that increased pre-ECMO ventilation duration is
associated with worse outcomes [16]. One of the exclu-
sion criteria in CESAR trial was high pressure (>30 cm
H2O of peak inspiratory pressure) and/or high FiO2
(>0.8) ventilation >7 days [2]. In our patient the dur-
ation of pre-ECMO invasive ventilation was very short
and this could be one of the contributing factor for his
improved outcome. Fifty percent of the reported cases
survived to hospital discharge. It is interesting to note
that the patients who survived had a shorter duration
of ECMO support (mean 9.25 versus 41 days). Advanced
patient age, increased pre-ECMO ventilation duration,
diagnosis category and complications while on ECMO are
some of the factors associated with adverse outcomes in
patients receiving ECMO support [17].
Patients in need of V-V ECMO support have a high
predicted mortality, and implementing an invasive ther-
apy that requires central venous cannulation, systemic
anticoagulation, and exposure to an extracorporeal by-
pass circuit involves substantial risk. The most common
complication encountered in ECMO patients is bleeding.
Cannula site, surgical site, central nervous system and
gastrointestinal bleeding are the most frequent
hemorrhagic complications. Infection is also relatively
common, with culture proven infections occurring in
approximately 20 % of adult respiratory ECMO patients.
Mechanical complications such as oxygenator failure,
clotting, air in the circuit and tubing rupture are other
important considerations [18, 19].
In the CESAR trial [2], not all patients transferred to
the ECMO center received ECMO therapy. Despite this
their outcomes were better than those managed in con-
ventional treatment centers. This highlights the fact that
management of patients with severe respiratory failure
by a specialized team in units that have an ECMO-based
management protocol improves outcome. As such, we
have developed a ‘Severe Respiratory Failure’ team at our
hospital that receives referrals from ICUs across the
country. Their role is to evaluate and manage patients
with life threatening respiratory failure who fail conven-
tional ventilation.
Conclusion
V-V ECMO was an effective rescue therapy in HIV posi-
tive patient with an otherwise fatal respiratory failure
due to Pneumocystis pneumonia and air leak syndrome.
This case report emphasizes on the fact that the use of
ECMO support in HIV/AIDS patient is not always futile
and can be considered if the patient has favorable base-
line characteristics and the primary problem is respiratory
failure that has a reversible etiology. It also highlights the
role of ECMO in allowing ultra-protective lung ventilation
and preventing ventilator-induced lung injury in patients
with poorly compliant lungs.
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Table 3 Adult patients with HIV/AIDS and severe Pneumocystis jirovecii pneumonia requiring ECMO therapy
























55/M 4 No NR; NR; NR Veno-arterial 4 9 80,235 TMP/SMX Post-ECMO Survived to
hospital
discharge
Steppan [11] 39/M 8 Yes NR; NR; NR Veno-venous 14 69 6297 CLI + PI, then ATQ,
then TMP/SMX
Pre-ECMO Died on ECMO
Goodman
et al [12]
25/M NR No 63.6; 52.9; 7.38 Veno-venous 69 36 622,234 PI, then CLI + PQ,
then TMP/SMX
Pre-ECMO Died on ECMO
Goodman
et al [12]












24/M NR No 100; NR; NR Veno-venous 24 3 50,728 TMP/SMX, then







45/M NR Yes 50; NR; NR Veno-venous 57 33 113,000 TMP/SMX, CLI, PQ Pre-ECMO Died in hospital
post ECMO
Our patient 26/M 1 Yes 200; 109; 7.01 Veno-venous 6 84 907,302 TMP/SMX Post-ECMO Survived to
hospital
discharge
P/F ratio Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (mm Hg), PaCO2 Partial pressure of carbon dioxide in arterial blood (mm Hg), ART Antiretroviral therapy, TMP Trimethoprim,















AIDS: acquired immune deficiency syndrome; APTT: activated partial
thromboplastin time; ARDS: acute respiratory distress syndrome;
BAL: broncho-alveolar lavage; BMI: body mass index; CT: computerized
tomography; ELSO: extra-corporeal life support organization; FiO2: fraction of
inspired oxygen; HIV: human immunodeficiency virus; MICU: medical
intensive care unit; NIV: non-invasive ventilation; PaCO2: partial pressure of
carbon dioxide in arterial blood; PaO2: partial pressure of oxygen in arterial
blood; PCR: polymerase chain reaction; PCV: pressure control ventilation;
PEEP: positive end expiratory pressure; PIP: peak inspiratory pressure;
PSV: pressure support ventilation; VILI: ventilator-induced lung injury; V-V
ECMO: veno-venous extra corporeal membrane oxygenation.
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